The first study that demonstrated that a subpopulation of cancer cells which survive drug treatment form viable drug-tolerant cells was the study of Sharma et al., who utilized targeted inhibition of the EGFR receptor in the EGFR-mutant non-small-cell lung cancer (NSCLC) line PC9 [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.